ttfields for lung cancer - how does it actually work and is it different for meso

William's right that the data for meso is its own thing, not just borrowed from NSCLC trials. The STELLAR trial specifically looked at pleural meso and showed median overall survival around 18 months with TTFields added to chemo, which was enough for FDA approval in 2019. That's the number worth asking your oncologist about directly.

From a legal standpoint, and I know that's not exactly what you asked, the timing of your diagnosis relative to your Oriskany service matters a lot. Hull techs had exposure patterns that varied by which maintenance cycles they were on, and that specificity can affect how a claim gets structured depending on the jurisdiction you file in.

On the vest question... from what clients have described to me, the bigger daily life issue isn't the equipment itself, it's the 18 hours a day compliance target. Some people adapt fast, some find it genuinely disruptive to sleep. That's worth a real conversation with whoever is fitting the device, not just the oncologist.

Consult your own attorney for anything specific to your situation, but the 2019 approval date matters for certain trust fund timelines too.

Not a medical answer here, just some context from the legal side that might help you think through this.

What I can tell you is that TTFields for pleural meso got FDA breakthrough designation back around 2019, and the STELLAR trial data showed some promising numbers for mesothelioma specifically. The mechanism you described is right, it disrupts mitotic spindle formation during cell division. Meso cells divide differently than typical NSCLC cells, which is part of why the field parameters are actually calibrated differently for pleural disease.

The vest situation is real. Clients I've worked with who went through TTFields treatment described wearing it 18 or more hours a day as the target, and that compliance window matters a lot for efficacy. Some found it manageable, some struggled with the adhesive array irritation after a few weeks. Being retired probably does work in your favor there.

From what I've seen in cases involving post-pleurectomy meso patients, Stage II with clean margins puts you in a meaningfully different position than someone dealing with bulkier residual disease. Whether TTFields makes sense at that stage is genuinely a question for your oncology team, maybe even a second opinion from somewhere like MD Anderson or Penn that sees higher meso volume than most centers.

The Oriskany service and your hull tech work is exactly the kind of exposure history we look at carefully. If you haven't already had a conversation about your legal options alongside the medical ones, that's worth doing sooner rather than later given how statutes of limitations vary by state.

Always consult an attorney for your specific situation.

Not my area of expertise medically, but I've worked alongside a lot of meso clients going through TTFields and I can share what I've seen from the legal and practical side of things.

The mechanism you described is right, alternating electric fields disrupting mitosis in rapidly dividing cells. For pleural meso specifically, the STELLAR trial published around 2019 showed median overall survival of around 18 months when TTFields was combined with chemo, which got people's attention because that number had been stubbornly low for years. The lung cancer data comes from a different trial population, so the two aren't really apples to apples, which is probably why your oncologist at EVMS is being careful about framing it as a possible add-on rather than a done deal.

The guys I've talked to who did it said the vest and transducer arrays are genuinely manageable day to day, especially if you're retired. Compliance matters a lot, the data suggests you want to be wearing it upwards of 18 hours a day to get the benefit. Skin irritation under the arrays was the most common complaint I heard. Not debilitating, but real.

From where I sit the bigger thing I'd want to understand in your position is whether your pleurectomy in August and your Oriskany service have been fully documented together. Stage II with clean margins is a meaningful situation legally and medically. There may be trust fund claims or litigation options that run on their own timeline regardless of your treatment path.

But please, consult an attorney familiar with your specific situation and jurisdiction before making any decisions on that side of things.